Cover Image
市場調查報告書

PharmaSphere:新的生物科技 - 基因治療市場分析

PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis

出版商 GlobalData 商品編碼 333931
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
PharmaSphere:新的生物科技 - 基因治療市場分析 PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis
出版日期: 2015年06月01日 內容資訊: 英文 101 Pages
簡介

本報告提供全球基因治療市場趨勢的相關調查、最近的企業、產業中引人注目的配合措施、現在進行的臨床試驗的詳細資料、主要的基因治療相關經營者簡介、各種聯盟、協定、契約等狀況等彙整資料。

第1章 目錄

第2章 簡介

第3章 基因治療概要

  • 基因治療是什麼?
  • 基因治療
    • 病毒載體
    • 非病毒載體與裸露DNA

第4章 市場發展

  • 轉折點:Glybera的認證
  • GSK:向EMA申請ADA-SCID的基因治療
  • Celladon:重病心臟衰竭的MYDICAR治療的陰性結果報告
  • Spark:SPK-CHM開始無脈絡脈畸型治療的第一/二階段臨床試驗
  • FDA:核准Sangamo的IND的β地中海型貧血基因治療的開始臨床試驗
  • 基因治療的支付:養老金模式

第5章 臨床試驗

  • 概要
  • 企業
  • 階段
  • 治療領域
  • 適應症
  • 實驗者
    • 專門
    • 國家

第6章 企業分析

  • 概要
    • 企業類型
    • 地區
  • 財務焦點
    • 收益
    • R&D支出
    • 市場資本化
    • 股票價格的效能
  • 開發平台簡介
    • Advantagene
    • ALS Therapy Development Institute
    • Amarna Therapeutics
    • American Gene Technologies International
    • AnGes MG
    • Applied Genetic Technologies Corporation
    • Asklepios BioPharmaceutical
    • Avalanche Biotechnologies
    • Bluebird bio
    • Celladon
    • Dimension Therapeutics
    • GeneCure Biotechnologies
    • Genethon
    • GenSight Biologics
    • Oxford BioMedica
    • ReGenX Biosciences
    • Sangamo BioSciences
    • Spark Therapeutics
    • UniQure
    • Voyager Therapeutics

第7章 各種契約狀況

  • 概要
  • 契約類型
    • M&A
    • 授權&聯盟
    • 資金籌措

第8章 策略性展望

第9章 附錄

圖表

目錄
Product Code: GDHC014PSR

GlobalData's "PharmaSphere: Emerging Biotechnologies - Gene Therapy Market Analysis" report is an essential source of information and analysis on the gene therapy field. Using detailed company data, deal analysis, corporate strategy, and market trends analysis, GlobalData provides an in-depth analysis of the current and future growth drivers of the gene therapy market. The report discusses the key factors shaping and driving the gene therapy business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of gene therapies.

Highlights

Key Questions Answered

  • What are the drivers of the gene therapy field?
  • Who are the leading companies involved in the development of gene therapies?
  • What are the major trends in gene therapy clinical trials?
  • What specific therapeutic areas and indications are receiving the most clinical research?
  • What progress has been made in terms of viral vector technology and gene delivery?
  • What specific business development activities are taking place in terms of partnerships or mergers and acquisitions (M&As)?
  • Has investor confidence been restored in the gene therapy field?

Scope

  • This report provides market developments across the gene therapy field, including clinical trials, deals, and pipeline investments
  • Investment examined on both the industry and financial communities
  • Broad discussion on the science behind gene therapies, viral vectors, and gene delivery
  • Clinical trials activity examined across phase of development, therapy area, and indication.
  • This report offers a deep dive into the synergies behind partnering and acquisition activity
  • Deals activity examined across geography, entity type, company, financial advisor, phase of development, therapy area, indication, and mechanism of action
  • Pipeline profiles of 20 leading biotech companies developing gene therapies

Reasons to buy

  • Identify the key players in the gene therapy market
  • Analyze and track the strategies that companies are using to strengthen their position in the gene therapy field; independent source for due diligence
  • Organize your sales and marketing strategy to identify companies with proprietary technologies in order to maximize opportunities for licensing, partnership, investment, or takeover
  • Understand the flow of investment from capital markets into the gene therapy field

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Report Scope
  • 2.2. Companies Mentioned
  • 2.3. Upcoming Reports
  • 2.4. Recently Published Reports

3. Gene Therapy Overview

  • 3.1. What is Gene Therapy?
  • 3.2. Gene Delivery
    • 3.2.1. Viral Vectors
    • 3.2.2. Non-Viral Vectors and Naked DNA

4. Market Developments

  • 4.1. Turning Point: Glybera Approval
  • 4.2. GSK Files Application to the EMA for Gene Therapy for ADA-SCID
  • 4.3. Celladon's Reports Negative Results for Mydicar in Advanced Heart Failure
  • 4.4. Spark Initiates Phase I/II Clinical Trial of SPK-CHM for Choroideremia
  • 4.5. FDA Accepts Sangamo's IND to Begin Trial of Gene Therapy for Beta-Thalassemia
  • 4.6. Paying for Gene Therapies: Annuity Model

5. Clinical Trials

  • 5.1. Overview
  • 5.2. Company
  • 5.3. Phase of Development
  • 5.4. Therapy Area
  • 5.5. Indication
  • 5.6. Investigators
    • 5.6.1. Specialty
    • 5.6.2. Country

6. Company Analysis

  • 6.1. Overview
    • 6.1.1. Entity Type
    • 6.1.2. Regional Split
  • 6.2. Financial Highlights
    • 6.2.1. Revenue
    • 6.2.2. R&D Spending
    • 6.2.3. Market Capitalization
    • 6.2.4. Stock Performance
  • 6.3. Pipeline Profiles
    • 6.3.1. Advantagene
    • 6.3.2. ALS Therapy Development Institute
    • 6.3.3. Amarna Therapeutics
    • 6.3.4. American Gene Technologies International
    • 6.3.5. AnGes MG
    • 6.3.6. Applied Genetic Technologies Corporation
    • 6.3.7. Asklepios BioPharmaceutical
    • 6.3.8. Avalanche Biotechnologies
    • 6.3.9. Bluebird bio
    • 6.3.10. Celladon
    • 6.3.11. Dimension Therapeutics
    • 6.3.12. GeneCure Biotechnologies
    • 6.3.13. Genethon
    • 6.3.14. GenSight Biologics
    • 6.3.15. Oxford BioMedica
    • 6.3.16. ReGenX Biosciences
    • 6.3.17. Sangamo BioSciences
    • 6.3.18. Spark Therapeutics
    • 6.3.19. UniQure
    • 6.3.20. Voyager Therapeutics

7. Deals Landscape

  • 7.1. Overview
    • 7.1.1. Geography
    • 7.1.2. Entity Type
    • 7.1.3. Company
    • 7.1.4. Stage
    • 7.1.5. Therapy Area
    • 7.1.6. Indication
    • 7.1.7. Mechanism of Action
  • 7.2. Deal Type
    • 7.2.1. Mergers and Acquisitions
    • 7.2.2. Licensing and Partnerships
    • 7.2.3. Capital Raisings

8. Strategic Outlook

9. Appendix

  • 9.1. Bibliography
  • 9.2. Research Methodology
    • 9.2.1. Coverage
    • 9.2.2. Secondary Research
  • 9.3. About the Author
    • 9.3.1. Adam Dion, Senior Industry Analyst
  • 9.4. Global Head of Healthcare
  • 9.5. About the Industry Dynamics Team
  • 9.6. About GlobalData
  • 9.7. Disclosure Information
  • 9.8. Disclaimer

List of Tables

  • Table 1: Common Diseases for Gene Therapy, Defects and Target Cells
  • Table 2: Main Groups of Viral Vectors and Their Characteristics
  • Table 3: Advantagene
  • Table 4: ALS Therapy Development Institute
  • Table 5: Amarna Therapeutics
  • Table 6: American Gene Technologies International
  • Table 7: AnGes MG
  • Table 8: Applied Genetic Technologies Corporation
  • Table 9: Asklepios BioPharmaceutical
  • Table 10: Avalanche Biotechnologies
  • Table 11: Bluebird bio
  • Table 12: Celladon
  • Table 13: Dimension Therapeutics
  • Table 14: GeneCure Biotechnologies
  • Table 15: Genethon
  • Table 16: GenSight Biologics
  • Table 17: Oxford BioMedica
  • Table 18: ReGenX Biosciences
  • Table 19: Sangamo BioSciences
  • Table 20: Spark Therapeutics
  • Table 21: UniQure
  • Table 22: Voyager Therapeutics
  • Table 23: Gene Therapy, M&A Deals Table Summary, 2010-2014
  • Table 24: Gene Therapy, Licensing Deals Table Summary, 2009-2015
  • Table 25: Gene Therapy, Capital Raisings Table Summary, 2013-2015

List of Figures

  • Figure 1: Number of Gene Therapy Clinical Trials, 2009-2014
  • Figure 2: Number of Gene Therapy Clinical Trials by Indication and Stage
  • Figure 3: Gene Therapy Clinical Trials by Company
  • Figure 4: Gene Therapy Clinical Trials by Phase of Development
  • Figure 5: Gene Therapy Clinical Trials by Therapy Area
  • Figure 6: Gene Therapy Clinical Trials, Percentage by Therapy Area
  • Figure 7: Gene Therapy Clinical Trials, Top Indications
  • Figure 8: Investigators by Specialty, Gene Therapy
  • Figure 9: Investigators by Country, Gene Therapy
  • Figure 10: Gene Therapy Companies, Entity Type
  • Figure 11: Gene Therapy Companies, Regional Split
  • Figure 12: Gene Therapy Companies by Revenue ($m), 2013
  • Figure 13: Gene Therapy Companies by R&D Spending ($m), 2013
  • Figure 14: Gene Therapy Companies by Market Capitalization ($m)
  • Figure 15: Leading Gene Therapy Companies, Stock Performance ($USD)
  • Figure 16: Gene Therapy Deals, Total Number of Deals and Deal Values ($m), 2009-2015
  • Figure 17: Gene Therapy Deals, Deal Value ($m) by DealType, 2014
  • Figure 18: Gene Therapy Deals, Number of Deals and Deal Values ($m) by Region, 2009-2015
  • Figure 19: Gene Therapy Deals by Region, 2009-2015
  • Figure 20: Gene Therapy Deals by Region, Deal Value ($m), 2009-2015
  • Figure 21: Gene Therapy Deals by Entity Type, Private vs. Public, 2009-2015
  • Figure 22: Gene Therapy Deals, Number of Deals and Deal Values ($m) by Company, 2009-2015
  • Figure 23: Gene Therapy Deals, Number of Deals and Deal Values ($m), by Product Stage, 2009-2015
  • Figure 24: Gene Therapy Deals, Number of Deals and Deal Values ($m), by Therapy Area, 2009-2015
  • Figure 25: Gene Therapy Deals by Indication, (>$500m), 2009-2015
  • Figure 26: Gene Therapy Deals by Indication, (<$500m), 2009-2015
  • Figure 27: Gene Therapy Deals, Number of Deals and Deal Values ($m) by Mechanism of Action, 2009-2015
  • Figure 28: Gene Therapy Deals, Number of M&A Deals and Deal Values ($m), 2010-2015
  • Figure 29: Gene Therapy, Number of Licensing Deals and Deal Values ($m), 2009-2015
  • Figure 30: Gene Therapy, Number of Capital Raisings and Deal Values ($m), 2009-2015
  • Figure 31: Gene Therapy, Number of Capital Raisings by Financial Advisor, 2009-2015
Back to Top